Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

Psychotropic medication use in adolescents with intellectual disability living in the community

dc.contributor.authorDoan, Tan
dc.contributor.authorWare, Robert S
dc.contributor.authorMcPherson, Lyn
dc.contributor.authorvan Dooren, Kate
dc.contributor.authorBain, Christopher
dc.contributor.authorCarrington, Suzanne
dc.contributor.authorEinfeld, Stewart
dc.contributor.authorTonge, Bruce
dc.contributor.authorLennox, Nicholas
dc.date.accessioned2015-12-13T22:26:59Z
dc.date.issued2014
dc.date.updated2015-12-11T08:26:37Z
dc.description.abstractPurpose: Information on the use of psychotropic medications in adolescents with intellectual disability is scant. Such information can guide interventions to improve psychotropic medication use in this population. We investigated the prevalence of, and factors associated with, psychotropic medication use in adolescents with intellectual disability in Australia who live in the community. Methods: Cross-sectional data were obtained from adolescents with intellectual disability living in the community in South East Queensland, Australia, between February 2007 and September 2010. Self-reported information on medication use was extracted from a health screening tool. Demographic and medical data were collected through parent/caregiver surveys. Medications were classified according to the Anatomical Therapeutic Chemical classification system. Psychopathology was assessed using the Developmental Behaviour Checklist Short Form. Logistic regression analysis was used to assess the association of demographic and medical characteristics with psychotropic medication use. Results: There were 176 participants (median age=16years, range=11-19years; 55% male). Psychotropics were used by 20% of participants. Psychostimulants were the commonest psychotropic class, used by 9% of participants. Multipsychotropic prescribing was not common with only seven participants using more than one psychotropic agent. After adjusting for potentially confounding variables, use of psychotropic medications was significantly associated with male gender (adjusted odds ratio=3.6; 95% confidence interval=1.3-9.5) and having major behaviour problems (3.1; 1.1-8.9). Conclusions: Adolescents with intellectual disability use a wide range of psychotropic medications. Being male and having major behaviour problems are associated with the use of psychotropic medications. Research examining the rationale for psychotropic prescribing in this population is needed.
dc.identifier.issn1053-8569
dc.identifier.urihttp://hdl.handle.net/1885/73739
dc.publisherJohn Wiley & Sons Inc.
dc.sourcePharmacoepidemiology and Drug Safety
dc.titlePsychotropic medication use in adolescents with intellectual disability living in the community
dc.typeJournal article
local.bibliographicCitation.issue1
local.bibliographicCitation.lastpage76
local.bibliographicCitation.startpage69
local.contributor.affiliationDoan, Tan, The University of Queensland
local.contributor.affiliationWare, Robert S, University of Queensland
local.contributor.affiliationMcPherson, Lyn, The University of Queensland
local.contributor.affiliationvan Dooren, Kate, The University of Queensland
local.contributor.affiliationBain, Christopher, College of Medicine, Biology and Environment, ANU
local.contributor.affiliationCarrington, Suzanne, Queensland University of Technology
local.contributor.affiliationEinfeld, Stewart, University of Sydney
local.contributor.affiliationTonge, Bruce, Monash University
local.contributor.affiliationLennox, Nicholas, The University of Queensland
local.contributor.authoruidBain, Christopher, u1813548
local.description.embargo2037-12-31
local.description.notesImported from ARIES
local.identifier.absfor111500 - PHARMACOLOGY AND PHARMACEUTICAL SCIENCES
local.identifier.ariespublicationU3488905xPUB3809
local.identifier.citationvolume23
local.identifier.doi10.1002/pds.3484
local.identifier.scopusID2-s2.0-84891633839
local.identifier.thomsonID000329177700010
local.type.statusPublished Version

Downloads

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
01_Doan_Psychotropic_medication_use_in_2014.pdf
Size:
103.21 KB
Format:
Adobe Portable Document Format